PharmTech LCGC Sciex Webinar 11.10
|Articles|June 15, 2006

PerkinElmer acquires Spectral Genomics

PerkinElmer, Inc. (Shelton, Connecticut) announced the acquisition of Spectral Genomics, Inc. (Houston, Texas), a leading company in molecular karyotyping technology used to evaluate chromosomal abnormalities.

PerkinElmer, Inc. (Shelton, Connecticut) announced the acquisition of Spectral Genomics, Inc. (Houston, Texas), a leading company in molecular karyotyping technology used to evaluate chromosomal abnormalities.

Spectral Genomics? array products and analysis software help pharmaceutical, biotechnology, cytogenetic, and clinical researchers identify chromosomal abnormalities related to the study of cancer and pre- and post-natal genetic disorders. The company?s proprietary Array CGH provides high-resolution global views of the human genome, enabling researchers to identify the exact location of any chromosomal deletions and amplifications that can cause an increased risk of genetic disease.


Related to this article

Best of the Week: From Cancer Diagnostics to Smarter LC Method Development
This week, Chromatography Online’s coverage spanned lipidomics-based early cancer detection, career paths in separation science, machine learning and uncertainty-driven approaches to LC method development, new EU wastewater rules for pharmaceutical micropollutants, automated Separation Quality Factor (SQF) evaluation in chromatography data systems, and solutions to GLP-1 peptide analysis challenges.